Bosutinib cost effective versus dasatinib and nilotinib in CML.

Bosutinib appears to be cost effective compared with both dasatinib and nilotinib for second-line (2L) treatment in US patients with chronic phase chronic myeloid leukaemia (CP-CML), according to findings of a Pfizer-funded study published in I Applied Health Economics and Health Policy i . Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting Applied Health Economics and Health Policy: 12 Jul 2021. A partitioned survival oncology model populated with clinical trial data on overall survival (OS) and progression-free survival (PFS) was used to evaluate the cost effective of bosutinib versus dasatinib and nilotinib in patients with CP-CML, from a US payer perspective over a lifetime time horizon. [Extracted from the article]